Immutep (IMMP) Competitors

Immutep (NASDAQ:IMMP) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Which has more volatility & risk, IMMP or ANIP?

Immutep has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Does the MarketBeat Community favor IMMP or ANIP?

ANI Pharmaceuticals received 120 more outperform votes than Immutep when rated by MarketBeat users. However, 72.56% of users gave Immutep an outperform vote while only 64.48% of users gave ANI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Immutep	Outperform Votes 312 72.56%	Underperform Votes 118 27.44%
ANI Pharmaceuticals	Outperform Votes 432 64.48%	Underperform Votes 238 35.52%

Do institutionals and insiders hold more shares of IMMP or ANIP?

2.3% of Immutep shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 3.1% of Immutep shares are held by insiders. Comparatively, 12.7% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is IMMP or ANIP more profitable?

Immutep has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat Immutep's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immutep	N/A	N/A	N/A
ANI Pharmaceuticals	-1.28%	15.87%	6.88%

Do analysts rate IMMP or ANIP?

Immutep currently has a consensus price target of $8.50, suggesting a potential upside of 333.67%. ANI Pharmaceuticals has a consensus price target of $77.33, suggesting a potential upside of 40.35%. Given Immutep's stronger consensus rating and higher possible upside, research analysts clearly believe Immutep is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immutep	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
ANI Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Does the media prefer IMMP or ANIP?

In the previous week, Immutep had 4 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 8 mentions for Immutep and 4 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.23 beat Immutep's score of 0.32 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immutep	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings & valuation, IMMP or ANIP?

ANI Pharmaceuticals has higher revenue and earnings than Immutep.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immutep	$5.14M	55.47	-$28.01M	N/A	N/A
ANI Pharmaceuticals	$555.46M	2.09	$18.78M	-$0.55	-100.18

Summary

ANI Pharmaceuticals beats Immutep on 9 of the 16 factors compared between the two stocks.